NASDAQ : PHAR
Pharming Group N.V. — Key statistics
Healthcare · Biotechnology · Netherlands
Last price 12.23 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 868.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 861.02M |
| Enterprise Value | 787.23M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 684.01M |
| Shares Change (YoY) | +33.62% |
| Shares Change (QoQ) | +27.86% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 20.59% |
| Float | 696.57M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 43.34 |
| Forward PE | 28.82 |
| PS Ratio | 2.23 |
| Forward PS | 2.15 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 5.20 |
| P/FCF Ratio | 24.96 |
| P/OCF Ratio | 24.34 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 32.56 |
| EV / Sales | 2.04 |
| EV / EBITDA | 13.81 |
| EV / EBIT | 15.93 |
| EV / FCF | 22.82 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.23 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 1.89 |
| Debt / FCF | 3.32 |
| Interest Coverage | 8.50 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 8.70% |
| Return on Assets (ROA) | 6.37% |
| Return on Invested Capital (ROIC) | 15.76% |
| Return on Capital Employed (ROCE) | 12.46% |
| Weighted Average Cost of Capital (WACC) | 4.53% |
| Revenue Per Employee | $950,243 |
| Profits Per Employee | $59,413 |
| Employee Count | 407 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.76 |
Taxes
| Measure | Value |
|---|
| Income Tax | 10.15M |
| Effective Tax Rate | 29.56% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -8.80% |
| 50-Day Moving Average | 10.71 |
| 200-Day Moving Average | 13.78 |
| Relative Strength Index (RSI) | 70.11 |
| Average Volume (20 Days) | 14,136 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13,429 |
| Short Previous Month | 20,097 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 386.75M |
| Gross Profit | 339.06M |
| Operating Income | 49.42M |
| Pretax Income | 34.33M |
| Net Income | 24.18M |
| EBITDA | 57.01M |
| EBIT | 49.42M |
| Earnings Per Share (EPS) | $0.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 189.56M |
| Total Debt | 114.51M |
| Net Cash | 75.05M |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | 291.24M |
| Book Value Per Share | 0.43 |
| Working Capital | 222.43M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 35.37M |
| Capital Expenditures | -870,000 |
| Depreciation & Amortization | 7.59M |
| Net Borrowing | -16.17M |
| Free Cash Flow | 34.50M |
| FCF Per Share | $0.05 |
Margins
| Measure | Value |
|---|
| Gross Margin | 87.67% |
| Operating Margin | 12.78% |
| Pretax Margin | 8.88% |
| Profit Margin | 6.25% |
| EBITDA Margin | 14.74% |
| EBIT Margin | 12.78% |
| FCF Margin | 8.92% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.62% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.31% |
| FCF Yield | 4.01% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.10 |
| Price Target Difference | 187.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.36% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |